At the news
? BULLISHIMPACT 6/10 8-K filed Apr 6, 2026 at 09:24 ET
Oncolytics Biotech announced a scheduled Type C meeting with the FDA on April 16, 2026, to discuss a registrational pathway for pelareorep in combination with a checkpoint inhibitor for squamous cell anal carcinoma (SCAC). The company plans to propose a single-arm pivotal study enrolling 60–70 patients with objective response rate as the primary endpoint, supported by clinical data showing approximately 30% ORR and 17-month median duration of response.
- Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss a registrational pathway for pelareorep in SCAC.
- The proposed pivotal study is single-arm, enrolling 60–70 patients, with objective response rate (ORR) as the primary endpoint.
- Clinical data from Cohort 4 of the GOBLET study showed approximately 30% ORR and 17-month median duration of response in late-line SCAC patients.
- SCAC is a rare cancer with limited second-line treatment options, positioning pelareorep for a potentially efficient approval path.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access